DOP2018000103A - Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson. - Google Patents

Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson.

Info

Publication number
DOP2018000103A
DOP2018000103A DO2018000103A DO2018000103A DOP2018000103A DO P2018000103 A DOP2018000103 A DO P2018000103A DO 2018000103 A DO2018000103 A DO 2018000103A DO 2018000103 A DO2018000103 A DO 2018000103A DO P2018000103 A DOP2018000103 A DO P2018000103A
Authority
DO
Dominican Republic
Prior art keywords
dihydroisoquinolin
ethanone
dichlorophenyl
hydroxy
methyl
Prior art date
Application number
DO2018000103A
Other languages
English (en)
Spanish (es)
Inventor
Alan Stephenson Gregory
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2018000103A publication Critical patent/DOP2018000103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2018000103A 2015-10-23 2018-04-20 Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson. DOP2018000103A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245391P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
DOP2018000103A true DOP2018000103A (es) 2018-10-31

Family

ID=57233858

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000103A DOP2018000103A (es) 2015-10-23 2018-04-20 Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson.

Country Status (13)

Country Link
CN (1) CN108137506A (zh)
AR (1) AR106332A1 (zh)
AU (1) AU2016341115A1 (zh)
CA (1) CA2999332A1 (zh)
DO (1) DOP2018000103A (zh)
EA (1) EA201890525A1 (zh)
EC (1) ECSP18030976A (zh)
IL (1) IL257872A (zh)
MX (1) MX2018004794A (zh)
PE (1) PE20181296A1 (zh)
PH (1) PH12018500859A1 (zh)
TW (1) TW201725199A (zh)
WO (1) WO2017070068A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
US20220062265A1 (en) * 2018-12-18 2022-03-03 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
TWI825323B (zh) 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
CN117377470A (zh) 2021-03-08 2024-01-09 伊莱利利公司 美维达林和其他d1正向别构调节剂在幻觉和痴呆相关精神病的治疗中的用途
KR20230154968A (ko) 2021-03-09 2023-11-09 일라이 릴리 앤드 캄파니 파킨슨병 진행을 늦추기 위한 메비달렌 및 다른 d1 양성 알로스테릭 조절제의 용도
CN113264926A (zh) * 2021-05-31 2021-08-17 东北林业大学 一种牡荆素与利血平的共晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
WO2008109336A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
PH12018500859A1 (en) 2018-10-29
TW201725199A (zh) 2017-07-16
WO2017070068A1 (en) 2017-04-27
AR106332A1 (es) 2018-01-03
CN108137506A (zh) 2018-06-08
CA2999332A1 (en) 2017-04-27
AU2016341115A1 (en) 2018-04-12
EA201890525A1 (ru) 2018-09-28
MX2018004794A (es) 2018-06-19
ECSP18030976A (es) 2018-05-31
PE20181296A1 (es) 2018-08-07
IL257872A (en) 2018-06-03

Similar Documents

Publication Publication Date Title
DOP2018000103A (es) Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson.
PE20152032A1 (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-il
PL3399962T3 (pl) Kompozycja okulistyczna do leczenia choroby suchego oka
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2015001504A3 (en) Antibody formulations and methods
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
NZ746468A (en) Methods of treating ocular conditions
DK3463351T3 (da) Behandling til parkinsons sygdom
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
AR096462A1 (es) 4-(5-(4-CLOROFENIL)-2-(2-CICLOPROPILACETIL)-1,4-DIMETIL-1H-PIRROL-3-IL)BENECENSULFONAMIDA COMO MODULADOR DE a7 nAChR
PH12016502235A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
ZA201902715B (en) Enzyme composition for therapeutic management of muscle soreness
MA40065A (fr) N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
EA201692485A1 (ru) Новая полиморфная форма n-[2-(6-фтор-1h-индол-3-ил)этил]-3-(2,2,3,3-тетрафторпропокси)бензиламина гидрохлорида для лечения болезни альцгеймера
MA47193A (fr) Formes posologiques solides d'inhibiteurs bace1 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridine
EA201790231A1 (ru) Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза
EP3113779A4 (en) Methods of treating a bruton's tyrosine kinase disease or disorder